1-3 of 3
William Bellamy, PhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Autologous Expanded Natural Killer Cells As a New Therapeutic Option for High-Risk Myeloma

Tarun K. Garg, PhD, Junaid Khan, Susann Szmania, Amy D Greenway, Joshuah D Lingo, Amberly Moreno-Bost, Katie Stone, Antje Hoering, PhD, Emily Woods, Bijay Nair, MD, William Bellamy, PhD, Dario Campana, MD, PhD, Shmuel Yaccoby, PhD, Bart Barlogie, MD, Ph.D, Joshua Epstein, DSc, Frits van Rhee, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2918.
https://doi.org/10.1182/blood.V118.21.2918.2918
Published: 2011
Journal Articles

Phase II Randomized Trial of Bevacizumab Versus Bevacizumab and Thalidomide for Relapsed/Refractory Multiple Myeloma.

George Somlo, MD, William Bellamy, PhD, Todd M. Zimmerman, MD, Paul Frankel, PhD, Joe Tuscano, MD, Margaret O’Donnell, MD, Ann Mohrbacher, MD, Stephen Forman, MD, Helen Chen, MD, James Doroshow, MD, David Gandara, MD
Journal: Blood
Blood (2005) 106 (11): 2571.
https://doi.org/10.1182/blood.V106.11.2571.2571
Published: 2005
Journal Articles

Expression of VEGF, VEGF Receptors, and Other Angiogenic Markers in Relapsed Aggressive Non-Hodgkin’s Lymphoma : Correlative Sudies from the SWOG S0108 Trial.

Alison Stopeck, MD, Maria Iannone, BA, Lisa Rimsza, MD, Thomas Miller, MD, Richard Fisher, MD, William Bellamy, PhD
Journal: Blood
Blood (2004) 104 (11): 2288.
https://doi.org/10.1182/blood.V104.11.2288.2288
Published: 2004